Actively Recruiting
Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients
Led by Istanbul University - Cerrahpasa · Updated on 2025-06-15
51
Participants Needed
1
Research Sites
57 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. By investigating these interventions, the investigators seek to introduce novel approaches that can enhance pulmonary function, exercise capacity, and overall quality of life for these patients. In the study, which will involve three groups-the control group, the inspiratory muscle training (IMT) group, and the Baduanjin group-it was calculated that a total of 51 patients, with 17 in each group (n = 17), should be included. The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other days. The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
CONDITIONS
Official Title
Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
- Clinically and hemodynamically stable (patients with NYHA Class I and II)
- Patients over 18 years of age
- Patients who provide informed consent
You will not qualify if you...
- Acute decompensated heart failure
- Decreased ejection fraction (<40%)
- Unstable angina pectoris
- Significant coronary artery disease (CAD)
- Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/m²)
- Uncontrolled hypertension (despite medication)
- Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
- Severe neurological disorders causing autonomic dysfunction
- Cognitive impairment that prevents communication
- Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istanbul University-Cerrahpasa (IUC) Cardiology Institute
Istanbul, Turkey (Türkiye)
Actively Recruiting
Research Team
R
Rengin Demir, Prof
CONTACT
V
Veysel Oktay, Assoc Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here